

Henry Ford Health

Henry Ford Health Scholarly Commons

Urology Articles

Urology

5-30-2022

ASO Visual Abstract: Anti-androgen Therapy Overcomes the Time Delay in Initiation of Salvage Radiation Therapy and Rescues the Oncological Outcomes in Men with Recurrent Prostate Cancer After Radical Prostatectomy-A Post Hoc Analysis of the RTOG 9601 Trial Data

Akshay Sood

Jacob Keeley

Isaac Palma-Zamora

Michael Chien

Nicholas Corsi

See next page for additional authors


Follow this and additional works at: https://scholarlycommons.henryford.com/urology_articles

Authors

Akshay Sood, Jacob Keeley, Isaac Palma-Zamora, Michael Chien, Nicholas Corsi, Wooju Jeong, Craig G. Rogers, Quoc-Dien Trinh, James O. Peabody, Mani Menon, and Firas Abdollah



ASO Visual Abstract: Anti-androgen Therapy Overcomes the Time Delay in Initiation of Salvage Radiation Therapy and Rescues the Oncological Outcomes in Men with Recurrent Prostate Cancer After Radical Prostatectomy—A Post Hoc Analysis of the RTOG 9601 Trial Data

Akshay Sood, MD^{1,2,3} , Jacob Keeley, MS¹, Isaac Palma-Zamora, MD², Michael Chien, BS², Nicholas Corsi, BS², Wooju Jeong, MD², Craig G. Rogers, MD^{1,2}, Quoc-Dien Trinh, MD⁴, James O. Peabody, MD^{1,2}, Mani Menon, MD^{1,2,5}, and Firas Abdollah, MD^{1,2}

¹VCORE – Vattikuti Urology Institute Center for Outcomes Research, Analytics and Evaluation, Henry Ford Hospital, Detroit, MI; ²Vattikuti Urology Institute, Henry Ford Hospital, Detroit, MI; ³Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX; ⁴Division of Urological Surgery and Center for Surgery and Public Health, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA; ⁵Department of Urology, Icahn School of Medicine at Mount Sinai, New York, NY

In this post hoc analysis of a phase-III randomized clinical trial (<https://doi.org/10.1245/s10434-022-11892-8>), we show that poorer outcomes associated with late salvage radiation therapy (sRT) in patients with recurrent prostate

cancer may be rescued with delivery of concomitant anti-androgen therapy in patients who may have missed the window for early sRT.

© Society of Surgical Oncology 2022

First Received: 9 May 2022

Accepted: 12 May 2022

A. Sood, MD
e-mail: akshaysood@outlook.com

F. Abdollah, MD
e-mail: firas.abdollah@gmail.com

Published online: 30 May 2022

Anti-Androgen Therapy Overcomes the Time-Delay in Initiation of Salvage Radiation Therapy and Rescues the Oncological Outcomes in Men With Recurrent Prostate Cancer After Radical Prostatectomy: A Post-Hoc Analysis of the RTOG 9601 Trial Data

Question

It is not known whether use of concomitant anti-androgen therapy (AAT) in men undergoing 'delayed' salvage radiation therapy (sRT) for recurrent prostate cancer can improve oncological and survival outcomes.



Population


Data on 670 men who participated in the RTOG 9601 trial and experienced biochemical recurrence were extracted using the NCTN data archive platform.

Patients were stratified into 4 treatment groups:

- early sRT (pre-sRT PSA <0.7 ng/mL) with/without concomitant AAT
- late sRT (pre-sRT PSA ≥0.7 ng/mL) with/without concomitant AAT

Conclusion

Poorer outcomes associated with late-sRT for recurrent CaP may be rescued by concomitant AAT -> the 15-year overall mortality rates in the early sRT, early sRT with AAT, late sRT and late sRT with AAT groups were **22.9%**, **22.8%**, **40.1%** and **22.9%** (p=0.0039), respectively.



Sood, et al. *Ann Surg Oncol*.

Visual Abstract by @sood11, @DrFAbdollah for @AnnSurgOncol

ANNALS OF
SURGICAL
ONCOLOGY

ACKNOWLEDGMENT This manuscript was prepared using data from Dataset NCT00002874 from the NCTN Data Archive of the National Cancer Institute's (NCI's) National Clinical Trials Network (NCTN). Data were originally collected from clinical trial NCT00002874 ("Radiation Therapy with or without Bicalutamide for Recurrent pT3N0 Prostate Cancer after Radical Prostatectomy"). All analyses and conclusions in this manuscript are the sole responsibility of the authors and do not necessarily reflect the opinions or views of the clinical trial investigators, NCTN, or NCI.

DISCLOSURES Firas Abdollah is an advisor for GenomeDx Biosciences, Quoc-Dien Trinh is a speaker for Intuitive Surgical Inc., and Akshay Sood and Mani Menon are members of the IDEAL collaboration at University of Oxford. None of the other authors has any relevant disclosures, and none of the authors has any financial or nonfinancial interests that may be relevant to the submitted work.

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

FUNDING None.

DATA AVAILABILITY From the NCTN Data Archive of the National Cancer Institute (NCI's) National Clinical Trials Network (NCTN).